Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Kopera, D; Torrano, J; Soyer, HP.
Treating the invisible: Subclinical actinic keratosis detected by imiquimod
JEADV CLIN PRACT. 2023; 2(4): 786-791.
Doi: 10.1002/jvc2.216
Web of Science
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Kopera Daisy
- Co-Autor*innen der Med Uni Graz
- Soyer Hans Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BackgroundSkin in UV-exposed areas may develop UV-induced actinic damage in DNA sequences leading to proliferation of keratinocyte carcinoma, a type of non-melanoma skin cancer. Actinic keratosis (AK) represents early-stage in situ squamous cell carcinoma. It develops from the basal cell layer and may be present in subclinical stages, being reported as field cancerization, even before being clinically visible. Thus, we hypothesise that from the age of 50 + UV-exposed skin features subclinical forms of AKs without visible skin lesions.ObjectivesThis study aims at clarifying the existence of the clinically invisible, early stages of AKs on chronically UV-exposed skin without showing clinically evident features of AK.Methods46 volunteers (26 females and 20 males) aged 50+ with signs of moderate to severe UV-damage (photodamage) applied imiquimod 3.75% creme on their entire face every night for a 2-week period. All participants kept a diary noting onset, severity of inflammatory reactions, and unexpected side effects.ResultsMore than 90% of participants without clinical evidence of AK showed inflammatory reactions on topical treatment with imiquimod on their face demonstrating an interaction between UV-damaged mutated keratinocytes and the topically applied immunomodifier, thus proofing the presence of subclinical AKs.ConclusionsThe action of imiquimod is not restricted to visible AK lesions, but often includes their vicinity, suggesting that neoplastic processes are frequent at a cellular level, not confined to clinically evident lesions, supporting the concept of field cancerization. Thus, subclinical AKs do exist in an early, macroscopically invisible state and may be targeted by imiquimod or 5-FU. At this stage, AKs are being treated before diagnosis by usual clinical means, and well before potential progression to invasive squamous cell carcinoma (SCC). Eventually, imiquimod 3.75% cream could be recommended in UV-exposed skin to prevent the presumptive development of AK and later on, early SCC. UV-exposed areas may develop actinic damage leading to proliferation of keratinocyte carcinoma. This study aims at clarifying the existence of invisible stages of actinic keratosis (AK) on UV-exposed skin without clinically evident features of AK. Volunteers (n = 46) applied imiquimod 3.75% creme on their entire face nightly for 2 weeks. Over 90% showed inflammatory reaction demonstrating that subclinical AKs do exist invisibly and may be targeted by imiquimod (or 5-FU). Thus, AKs can be treated before diagnosis and well before progression to squamouscellcarcinoma.
- Find related publications in this database (Keywords)
- actinic keratosis
- immunomodulatory
- subclinical
- treatment